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Loss of the tumor suppressor gene PTEN is implicated in breast cancer
progression and resistance to targeted therapies, and is thought to
promote tumorigenesis by activating PI3K signaling. In a trans-
genic model of breast cancer, Pten suppression using a tetracycline-
regulatable short hairpin (sh)RNA cooperates with human epidermal
growth factor receptor 2 (HER2/neu), leading to aggressive andmet-
astatic disease with elevated signaling through PI3K and, surpris-
ingly, the mitogen-activated protein kinase (MAPK) pathway.
Restoring Pten function is sufficient to down-regulate both PI3K
and MAPK signaling and triggers dramatic tumor regression. Phar-
macologic inhibition of MAPK signaling produces similar effects to
Pten restoration, suggesting that the MAPK pathway contributes to
the maintenance of advanced breast cancers harboring Pten loss.
breast cancer | mouse models | tumor suppressors | RNAi |
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The PTEN (phosphatase and tensin homolog) tumor sup-pressor gene is mutated or silenced in a wide range of
tumor types (1). PTEN encodes a phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase that counters the action of the
phosphatidylinositol 3-kinases (PI3Ks), which otherwise transmit
growth factor signals from receptor tyrosine kinases to down-
stream mediators such as the AKT family of serine/threonine-
specific protein kinases (2). AKT, in turn, activates a series of
downstream effectors that promote cellular proliferation and
survival. Consequently, PTEN loss leads to hyperactivation of
the PI3K pathway, and it is widely believed that this is the pri-
mary mechanism whereby PTEN loss drives tumorigenesis (3).
Although cross-talk and feedback signaling makes the situation
more complex (4), this molecular framework provides a strong
rationale to target PI3K pathway components in PTEN-deficient
tumors, and indeed, a variety of small-molecule antagonists with
such activities are currently in clinical trials (5, 6).
Deregulation of the PI3K pathway is common in breast cancer
and most frequently occurs through mutations in phosphatidyli-
nositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)
(7). By contrast, PTENmutation or loss is less frequent at diagnosis
but instead is associated with disease progression (8, 9). For ex-
ample, PTEN inactivation often arises in oncogenic receptor ty-
rosine kinase human epidermal growth factor receptor 2 (HER2/
neu) amplified tumors in patients who acquire resistance to the
HER2/neu targeting agent trastuzumab (10–14). Similarly, PTEN
mutations were recently reported in a patient harboring PIK3CA
mutations that developed resistance to the PI3Kα inhibitor
BYL719 (15). Thus, PTEN inactivation occurs in advanced disease
in patients with poor prognosis, defining a breast cancer subtype
for which there is an unmet clinical need.
Studies using mouse models have confirmed the importance of
PI3K signaling in breast cancer (16). Transgenic mice that over-
express mutant PIK3CA in conjunction with HER2/neu re-
capitulate resistance to anti-HER2/neu therapies (17), and
conditionally overexpressed mutant PIK3CA in the mammary
gland gives rise to tumors at long latency that regress upon
oncogene withdrawal (18). Although these observations con-
tribute to the rationale for targeting PI3K pathway compo-
nents in breast cancer, they use a model in which mutant
PIK3CA is expressed at unphysiological levels and serves as
the initiating event. Furthermore, studies using conditional
knockout mice indicate that deregulation of the endogenous
PI3Ks indirectly through Pten inactivation can promote ad-
vanced disease in combination with HER2/neu (19, 20). Still,
whether sustained PTEN inactivation is needed for the main-
tenance of advanced cancers remains unknown. Resolving this
issue may reveal cellular dependencies and, as such, instruct the
clinical use of molecularly targeted agents attacking the PTEN
network. In this study, we explore the impact of genetic and
pharmacologic manipulation of the Pten pathway in breast
cancer. Unexpectedly, our results reveal that Pten loss is re-
quired to maintain advanced disease by enhancing signaling
through both the PI3K and mitogen-activated protein kinase
(MAPK) cascades.
Significance
PTEN mutations are associated with disease progression and
therapy resistance in human epidermal growth factor receptor 2
(HER2/neu)-amplified breast cancer patients but the role of PTEN
loss in breast cancer maintenance is unknown. Here, using a
regulatable RNAi mouse model of HER2/neu-driven metastatic
breast cancer, we show that Pten silencing accelerates disease
progression and that restoration of endogenous Pten expression
triggers marked disease regression. By comparing and con-
trasting how pharmacologic perturbations of various signaling
pathways compare to genetic reactivation of Pten, we identify a
requirement for Mek signaling in Pten-suppressed tumors. Our
findings imply that even advanced tumors can remain de-
pendent on Pten loss and provide a rationale for exploring the
utility of MEK inhibitors in therapy-resistant breast cancer pa-
tients acquiring PTEN mutations.
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Results
A Model for Mammary Gland-Specific Pten Silencing. Genetically
engineered mouse models (GEMMs) are powerful tools for the
study of gene function in disease (21, 22). We previously optimized
an efficient pipeline that implements recombinase-mediated cas-
sette exchange to introduce tet-responsive shRNAs into embryonic
stem cells at a defined genomic locus, thereby providing a platform
to explore the requirement for sustained gene loss in disease pro-
gression and maintenance (23, 24). To build a GEMM that enables
inducible and reversible knockdown of Pten in the mammary
epithelium, we bred mice carrying a whey acidic protein
(WAP) gene promoter-driven Cre transgene (25) and a CAGs-
LoxPStopLoxP-rtTA3-ires-mKate2 (CAGs-LSL-RIK) allele (26),
which together drive mammary luminal ductal epithelium-restricted
expression of a reverse tet-transactivator (rtTA3) and a far-red
fluorescent protein (mKate2) in response to lactogenic hormones.
The expression of rtTA3 enables doxycycline (dox)-dependent
GFP-linked shRNAs (TRE-GFP-miR30-shRNA or TG-shRNA)
to be expressed from a transgene integrated downstream of the
col1a1 locus (Fig. 1 A–C and Fig. S1A).
In this dual-color “Dox-On” system, mKate2 reports Cre recom-
binase activity and expression of rtTA3, whereas GFP fluorescence
identifies cells with shRNA expression and Pten silencing (23).
Noninvasive, in vivo imaging of fluorescent markers allows for de-
tection of transgene activation and longitudinal surveillance of tumor
progression (Fig. S1B). We used two transgenic shRNA strains that
demonstrate efficient Pten silencing to confirm that our phenotypes
were due to loss of Pten and not shRNA-specific off-target effects
(27). Luminal specific expression of shRNAs targeting Pten in post-
pregnancy (parous) adult animals conferred robust target protein
suppression (Fig. 1D and Fig. S1C) but did not result in morpho-
logical defects of the mammary glands (Fig. S1D). Both WAP-Cre/
CAGs-LSL-RIK/TG-shPten.1522 (abbreviated hereafter as shPten)
and WAP-Cre/CAGs-LSL-RIK/TG-shPten.2049 (shPten.2049) ani-
mals that were affected only by Pten knockdown did not develop
tumors for up to 300 d of dox treatment (n > 6 for both shRNAs).
Pten Loss Accelerates HER2/neu-Driven Disease Onset and Progression.
To drive breast tumor initiation, we included a mammary-specific
HER2/neu oncogene (MMTV-neuV664E) (28) (Fig. 1A). Continuous
postpartum dox treatment of WAP-Cre/CAGs-LSL-RIK/MMTV-
neuV664E/TG-shPten.1522 (abbreviated thereafter as shPten/neu)
animals led to the onset of palpable mammary tumor development
in 100% of mice at a median latency of 62 d (Fig. 2A). At this time
no control animals (WAP-Cre/CAGs-LSL-RIK/MMTV-neuV664E/
TG-shRenilla.713 or shRen/neu) showed palpable tumors (median
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AFig. 1. Mammary gland-specific expression of dox-
inducible miR30 shRNAs. (A) Schematic description of
the five transgenic alleles incorporated into the
“Dox-On” multiallelic model, with the CAGs-LSL-
rtTA3-IRES-mKate2 (CAGs-LSL-RIK) allele shown in its
configuration before and after Cre-mediated recombi-
nation upon lactogenic stimulus. This RIK transgene
contains a CMV early enhancer element and chicken
beta actin (CAGs) ubiquitous promoter upstream of the
LSL, followed by a modified reverse tet-transactivator
with increased dox sensitivity (rtTA3), internal ribosomal
entry site (IRES), and a monomeric far-red fluorescent
protein (mKate2). Because the lactation-induced WAP
promoter provides the tissue specificity, we opted for
the use of a ubiquitous promoter upstream of the
rtTA element such that its expression levels are
not modulated by changes in cellular state over
the course of tumorigenic transformation. Following
pregnancy, the CAGs promoter drives constitutive ex-
pression of rtTA3 and fluorescent reporter mKate2.
Once the luminal cells of the mammary ductal epi-
thelium express rtTA3, dox can be used to induce
expression of the shRNA transgenic allele TRE-GFP-
miR30-shRNA (TG-shRNA). The tetracycline-
responsive element promoter (TRE) is active when
bound by rtTA3, and GFP has been coupled with the
expression of the shRNA such that the strength of
the fluorescent signal corresponds inversely to the
knockdown level of the target protein. The resulting
model provides postadolescent, luminal epithelial-
specific knockdown of the target protein of interest.
(B) Time line of procedural steps for transgene activa-
tion including lactation and dox treatment. Experi-
mental animals (carrying either the Ren.713 control
shRNA or Pten shRNA) are generated as littermate co-
horts to control for the influence of the mixed genetic
background. Mice are mated at 7 wk of age after the
development of the mammary gland, and pregnancy
lasts 21 d. Lactation after litter birth induces the WAP
promoter, and as such dox treatment is started simul-
taneously to litter birth to induce shRNA expression.
Nursing pups are weaned after 3 wk, and experi-
mental mice are monitored weekly for onset of tu-
mor growth. (C) Representative images of immunofluorescence (IF) analysis of mammary glands from parous WAP-Cre/CAGs-LSL-RIK/TG-shRen.713
(abbreviated as “shRen”) control animals either with or without dox treatment. Fluorescent reporter mKate2 staining indicates cells expressing rtTA3. In the
presence of dox, rtTA3 binds the TRE promoter and drives expression of the GFP reporter and shRNA. (Scale bars: 20 μm.) (D) Representative images of IHC
analysis of mammary glands from parous, dox-treated shRen and shPten (abbreviation for WAP-Cre/CAGs-LSL-RIK/TG-shPten.1522) animals. GFP staining
indicates cells expressing miR30 shRNAs, and Pten protein loss is observed specifically in luminal ductal cells in shPten ducts. (Scale bars: 20 μm.)
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latency 170 d), demonstrating a strong synergistic effect of HER2/
neu overexpression and Pten depletion (Fig. 2A). As WAP-Cre in-
duction is linked to lactation, we confirmed that disease burden was
not related to the litter size of parous mice (Fig. S2A).
shPten/neu mice showed a dramatic decrease in overall sur-
vival compared with shRen/neu control animals, which eventually
succumb to the oncogenic effect of the HER2/neu transgene (Fig.
2B and Fig. S2B). Although every tumor harvested from shPten/
neu mice expressed the GFP and mKate2 fluorescent reporters,
in shRen/neu mice only one quarter (26%) of observed tumors
were GFP/mKate2-positive, indicating that Pten silencing pro-
moted accelerated tumor growth in a WAP-Cre allele-expressing
subpopulation of epithelial cells that does not overlap com-
pletely with the population of cells that express the MMTV-
neuV664E allele (Fig. S2C). A significant increase in disease
burden per mouse at end-stage disease was also seen in shPten/
neu mice (Fig. S2 D and E). These results recapitulate previous
studies using a conditional Cre-LoxP model of Pten loss (19, 20)
and highlight the effectiveness of the shRNA approach.
Pten protein depletion was consistently robust in shPten/neu tu-
mor tissue, which also expressed GFP (Fig. 2C). These areas also
displayed strong staining for HER2/neu at the cell membrane and a
high Ki-67 index, a marker for cellular proliferation (Fig. 2C and
Fig. S3A). Pten protein was detected in all tumors analyzed from
shRen/neu mice (n = 18/18; Fig. 2C), indicating that HER2/neu-
driven tumor development did not select for stochastic Pten loss.
Histopathology of primary mammary tumors revealed large nodular
nests with central necrosis, similar in morphology to the parental
MMTV-neuV664E strain (Fig. S3B). Both shRen/neu and shPten/neu
tumors at end-stage disease showed characteristics of human in-
vasive ductal carcinomas, with marked nuclear pleomorphism, high
mitotic count, and lack of tubule formation. Thus, the shPten/neu
mice develop tumors that reflect the most common malignant
breast tumor type in humans and show pathological characteristics
(high grade, poorly differentiated) that carry a poor clinical prog-
nosis. Immunohistochemical analysis revealed estrogen receptor
alpha (ERα) and CK19 expression in both control and Pten
knockdown tumors (Fig. S3A). In contrast, there was a decrease in
HER3/ErbB3 protein levels detected only in shPten/neu tumor tis-
sue (Fig. S3A), which, in line with previous observations (29, 30), is
suggestive of elevated PI3K/Akt activity and increased pathway
feedback. Collectively, these results demonstrate strong cooperation
between Pten loss and activated HER2/neu in a histopathologically
accurate model of luminal epithelial breast cancer.
We also noted increased metastatic burden in shPten/neu an-
imals (n = 19/21) compared with shRen/neu controls (n = 9/13) at
end-stage disease (Fig. S4 A and B). Histologically, lung metas-
tases resembled the primary tumors (Fig. S4C), showing strong
HER2/neu overexpression and Pten knockdown (Fig. S4D).
Importantly, key phenotypes (accelerated tumor initiation and
progression, lung metastasis, and histopathology) were validated
with two independent shRNAs targeting Pten (Fig. S5). Together,
our results demonstrate that shRNA-mediated Pten silencing has a
dramatic impact on tumor initiation and progression in HER2/neu-
mediated mammary tumorigenesis.
Restoration of Pten Causes Tumor Regression. To assess whether
sustained Pten loss is required for tumor maintenance, we took
advantage of the unique ability of regulated RNAi to reverse gene
silencing and restore endogenous Pten protein in established tu-
mors. For this, we identified a cohort of shPten/neu animals with
palpable tumors in at least one quadrant region (n = 19, 52–97 d
dox treated), withdrew dox to restore Pten expression, and mon-
itored tumor growth with caliper measurements and small animal
magnetic resonance imaging (MRI). Restoration of Pten protein
and loss of shRNA-linked GFP was confirmed in tumor tissue
2 wk after dox withdrawal (Fig. 3A).
Most tumors arising in shPten/neu mice showed dramatic, and
often complete, regression during the first 3 wk following dox
withdrawal (n = 15/17), whereas those in shPten/neu animals
maintained on dox exhibited exponential tumor growth (Fig. 3 B
and C). Tumor regression was indeed due to Pten protein resto-
ration, as tumors in the second shRNA strain, shPten.2049/neu,
displayed similar regression patterns whereas those arising in shRen/
neu control mice at long latency remained unaffected by dox
treatment withdrawal (Fig. S6). Neither total tumor burden at the
time of dox withdrawal nor duration of dox treatment before dox
withdrawal correlated with the maximal response in tumor re-
gression documented in each animal (Fig. S7). In most cases, tumor
regression was sustained for at least 50 d after dox withdrawal (Fig.
S8), leading to a significant increase in overall survival (Fig. 3D).
Nonetheless, multifocal disease relapse driven by HER2/neu over-
expression eventually occurred in almost all shPten/neu mice
maintained off dox (n= 18/19) (Fig. 3D). Still, this dramatic regression
of exponentially growing HER2/neu-driven mammary tumors upon
Pten restoration suggests that Pten knockdown not only accelerates
tumor initiation but also is required for tumor maintenance.
Pten Loss Drives PI3K/Akt and MAPK Signaling Pathways in HER2/neu
Mammary Tumors.We postulated that restoration of Pten protein
in Pten knockdown tumor tissue disrupts the signaling pathways
governing cellular proliferation and/or survival, leading to tumor
A C
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Fig. 2. Pten loss accelerates HER2/neu-driven disease
onset and progression. Kaplan–Meier (KM) curves for
cohorts of parous, dox-treated quadruple transgenic
mice (WAP-Cre/CAGs-LSL-RIK/MMTV-neuV664E/TG-shRNA
abbreviated as “shRNA/neu”with corresponding shRNA
target gene name) monitored weekly through palpa-
tion showing (A) tumor-free and (B) overall survival for
shPten/neu (n = 42) and shRen/neu (n = 46). Age has
been normalized to date of litter birth, which was also
the start of dox treatment in this experiment. (C) Rep-
resentative images of IHC analysis of primary tumor
tissue of parous, dox-treated shRen/neu and shPten/neu
mice at end-stage disease showing robust HER2/neu
overexpression in both cohorts and strong Pten protein
knockdown specifically in shPten/neu tumors. (Scale
bars: 100 μm.)
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shrinkage. To explore this in more detail, we performed immu-
nohistochemical (IHC) and immunoblot (IB) analyses of shRen/
neu and shPten/neu primary mammary tumors (Fig. 4 and Fig. S9A).
In regressing shPten/neu tumors examined 3 wk after dox with-
drawal, tumors showed reduced proliferation (as measured by
BrdU incorporation and Ki-67 staining) but no detectable increase
in apoptosis (as assessed by cleaved caspase-3 staining) (Fig.
S9B). Although these observations suggest that tumor shrinkage
was independent of apoptosis, we cannot rule out the possibility that
transient increases in signal were missed at the examined time point.
Consistent with the ability of Pten to suppress PI3K signaling, Pten
knockdown tumors showed an increase in Akt phosphorylation that
was not apparent in tumors arising in shRen/neumice (Fig. 4B). Akt
levels were suppressed upon Pten restoration, and notably, relapsed
tumors maintained re-expression of Pten (Fig. 4).
Unexpectedly, we also noted a consistent elevation in phosphor-
ylated Erk (p-Erk) levels in primary tumors and pulmonary metas-
tases arising in dox-treated shPten/neu mice compared with shRen/
neu mice, suggesting that Pten suppression triggered hyperactivation
of the MAPK pathway (Fig. 4 and Fig. S9C). Indeed, high p-Erk
expression was not merely a secondary event in tumors generated by
Pten knockdown, as restoration of endogenous Pten expression in
shPten/neu tumors led to a reproducible suppression of p-Erk levels
(Fig. 4). Consistent with the delay seen in the shPten/neu cohort
tumor regression response, Pten levels remained low at 7 d after dox
withdrawal (Fig. S9D) but returned to baseline by 14 d (Fig. 4B).
High p-Akt and p-Erk levels were sustained at 7 d post-dox with-
drawal but were suppressed at 2 wk. Thus, despite constitutive
overexpression of an overactive HER2/neu oncogene, restoration of
endogenous Pten induced a striking reduction in both PI3K/Akt and
Mek/Erk signaling that correlated with disease regression.
Confounding further in-depth analysis of the relapsed tumors is
the multifocal nature of the disease that develops in this GEMM.
Despite our capacity to track mKate2-expressing cells in the absence
of dox, given the large number of tumor-initiating events docu-
mented per mouse, it was difficult to determine whether the tumors
that progressed off dox were arising from relapses of an originally
responsive malignancy or rather from “background” tumors
expected to arise eventually from HER2/neu-expressing cells that
never expressed the Pten shRNA. Indeed, it seems most likely that
they represented a mixture of both classes, as some expressed high
levels of the lineage tracing mKate2 reporter linked to the rtTA3
(indicating they can express the Pten shRNA when dox treated)
whereas others did not. Regardless, all of the tumors that pro-
gressed showed abundant Pten expression and did not contain el-
evated p-Akt or p-Erk levels, indicating that secondary mechanisms
capable of recapitulating Pten loss were not acquired.
Mek Signaling Is Required to Maintain Tumors with Suppressed Pten.
The marked reduction in PI3K/Akt and Mek/Erk signaling following
Pten restoration prompted us to ask whether the activity of each
pathway was critical for disease progression and, thus, whether
pharmacological inhibition could also drive tumor regression. To
provide a controlled experimental setting for comparing different
treatment arms, we generated cohorts of matched secondary
transplants from primary tumor fragments harvested from shPten/
neu mice. These transplants showed consistent tumor growth (on
dox) and response to Pten restoration (dox withdrawn), mirroring
the primary disease in transgenic mice (Fig. 5). In all, we assessed
four treatment arms using agents targeting oncogenic HER2/neu
(Lapatinib), PI3K/Akt signaling (α-Akt: MK-2206; α-pan-PI3K:
NVP-BKM120), or Mek/Erk activity (α-Mek: GSK1120212) at
doses routinely used in preclinical studies (15, 29, 31, 32). Drug
efficacy against the mouse protein target was verified by assessing
the impact on signaling in treated tumor protein extracts (Fig. S10).
Consistent with the known role for PI3K pathway activation in
promoting resistance to HER2/neu inhibition (33, 34), Lapatinib
had only a mild effect in slowing tumor growth (Fig. 5A). By con-
trast, pan-PI3K and Akt inhibitors, as predicted, were effective in
suppressing tumor growth, although not nearly as efficiently as Pten
restoration. Surprisingly, Mek inhibition induced the most robust
tumor response, effectively blocking tumor growth over 4 wk of
treatment and phenocopying the effect of Pten restoration in these
transplants (Fig. 5A). Although counterintuitive to the canonical
A
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Fig. 3. Pten loss is required for tumor maintenance. (A) Representative images
of IHC analysis of hyperplastic ductal epithelium of the mammary gland or
mammary tumor of parous shPten/neu mice either continuously dox treated or
2 wk after dox withdrawal. (Scale bars: 100 μm.) (B) Representative axial plane
MRI images of continuously dox-treated (n = 2) and dox-withdrawn (n = 3) co-
horts of shPten/neu mice analyzed by MRI at days 0 and 14. (C) Waterfall plot
displaying percentage of change in total tumor burden volume per mouse at the
time point of 3 wk after dox withdrawal for a cohort of shPten/neumice (n = 17)
compared with a representative cohort of continuously dox-treated animals (n =
8). Dotted lines indicate +100 and −30% thresholds. (D) KM curve depicting the
overall survival benefit of animals after dox withdrawal (n = 19) compared with
dox-treated animals (n = 56; data partially presented in Fig. 2). Double arrow
indicates range of dox withdrawal start date.
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view of Pten as a regulator of PI3K signaling, our results suggest
that Pten loss, in addition to up-regulating the PI3K/Akt pathway,
causes a functional “cross-activation” of the MAPK pathway that
goes beyond the canonical HER2/neu-dependent signaling through
Erk and contributes significantly to aggressive tumor growth. Still, it
remains a possibility that pan-PI3K and Akt inhibition was less ef-
fective than Mek inhibition in our model due to differences in
pharmacokinetics, reduced activity against the mouse protein(s), or
PI3K-independent functions of Pten (35).
Discussion
Our findings are consistent with previous work in which withdrawal of
a conditional PIK3CA transgene used to initiate tumorigenesis also
produced marked disease regression (18). In our study, Pten in-
activation served as a cooperating event to promote tumorigenesis
together with the strong initiating driver HER2/neu. Even so, Pten
reactivation blunted PI3K and MAPK signaling, leading to a potent
antitumor response. Although these studies suggest that pharmaco-
logical strategies to achieve similar ends would be therapeutically
beneficial in advanced forms of breast cancer, the relative contribu-
tion of Pten loss to tumor maintenance may depend on tissue and/or
genetic context. Accordingly, we recently showed that the antitumor
effects of Pten reactivation in a mouse model of aggressive leukemia
were largely limited to leukemic cells at disseminated sites (27).
Additional studies will be required to fully elucidate the complex
cross-talk between the PI3K and MAPK pathways (4). Physiologi-
cally, PTEN-dependent early endodermal morphogenesis seems to
require the Erk, but not the Akt, pathway (36). Furthermore, in Ras-
induced oncogenic transformation, PTEN apoptotic function is sup-
pressed via the Raf-Mek-Erk pathway (37). Recent publications using
human breast cancer cell lines support the notion that PI3K in-
hibition can involve an ERK-dependent component (38, 39). In one
study, this effect was apparently mediated by the phosphatidylinositol
3,4,5-trisphosphate-dependent Rac exchanger 1 (P-Rex1), which ac-
tivates Rac1, leading to MAPK pathway activation. In another,
enforced expression of PTEN caused a decrease in p-ERK levels.
Both confirm that combined inhibition of MEK in conjunction with
PI3K or AKT improved antitumor efficacy in breast cancer xeno-
grafts. These data are in agreement with earlier reports showing that
expression of functionally active PTEN inhibits ERK activation in
glioblastoma models (40). Moreover, ectopic expression of PTEN in
MCF7 cells results in both AKT and ERK suppression, but only
specific inhibition of MEK can abolish the negative effects of PTEN
on insulin-mediated cell growth (41).
Our finding that shPten/neu primary tumor regression upon
restoration of Pten protein levels is dependent on both PI3K/Akt
and MAPK pathways reiterates the presence of a complex and
interconnected signaling cross-talk network that regulates these
tumors’ sustained survival and proliferative advantage in a rel-
evant physiological context. Collectively, these data provide a
strong rationale for combining agents that target the MAPK
A B
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p-Erk T202/Y204
-+++ + -+ -+ - -+
p-Akt Ser473
-
p-Mek S217/221
p-Akt Thr308
Akt total
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Actin
Erk total
mKate2
Fig. 4. Heightened PI3K/Akt and MAPK pathway signaling in Pten knockdown tumors. IHC (A) and IB (B) analysis of end-stage disease mammary tumors of parous
shRen/neu and shPten/neu mice either continuously dox treated or dox withdrawn. (Scale bars: 100 μm.) For B, unsorted whole tumor protein lysate was analyzed.
A
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Fig. 5. Pharmacologic inhibition of MAPK pathway recapitulates Pten resto-
ration. (A) Dox-treated shPten/neu animal-derived primary tumor fragment
serial transplantation assay in nude mice. Mice were treated with or without
dox with a drug or vehicle (n = 12–14 tumors). Drug dosages: GSK1120212
(3mg/kg daily), MK-2206 (360mg/kg daily and then twice weekly after day 14),
NVP-BKM120 (31.35 mg/kg daily), and Lapatinib (100 mg/kg daily). Data repre-
sent mean ± SEM. (B) Representative mKate2 and GFP fluorescence images from
in vivo Xenogen IVIS Spectrum imaging of dox-treated and dox-withdrawn (day
10) nude mice from the tumor fragment transplantation assay.
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and PI3K pathways, especially in the absence of PTEN (42). As
PTEN loss is linked to resistance against anti-HER2/neu agents
or single PI3K inhibitors, such combinatorial approaches would
address an unmet clinical need.
Materials and Methods
Mouse Strains, Animal Husbandry, and Tumor Cohorts. All mouse strains
have been previously described. MMTV-neuV664E [strain name: FVB-Tg(MMTV-
Erbb2)NK1Mul/J] (28) and WAP-Cre [strain name: B6.Cg-Tg(Wap-cre)11738Mam/
JKnwJ] (25) were purchased from Jackson Laboratory. In the MMTV-neuV664E al-
lele, an activating point mutation (V664E) in the transmembrane domain of neu
results in increased receptor homodimerization and constitutive activation of the
kinase domain (43). The strains CAGs-LSL-RIK (26), TG-shRenilla-Luciferase.713 (23),
TG-shPten.1522 (27), and TG-shPten.2049 (27) were made by the S.W.L. labora-
tory. Transgenic strains were not backcrossed onto the same strain background
before mating; thus all experimental animals were generated on a mixed strain
background. The mating strategy was conducted such that the experimental
shRNA and the control shRNA animals were born as littermates. Mice were
housed in vented cages with a 12-h light cycle and food and water ad libitum.
Experimental female animals, after PCR verification for the correct genotypes,
were bred at 7 wk, and doxycycline feed was administered from the date of litter
birth. Litters were nursed for 3 wk to induce WAP promoter activity. Parous mice
underwent only one pregnancy cycle. Parous mice were monitored weekly,
blinded from genotypic information, for tumor formation by physical palpation.
Tumor and organ tissue samples were excised from humanely euthanized mice
and either fixed and/or snap-frozen. Caliper measurements during tumor re-
gression experiments were used to estimate tumor volume with the
formula V = (4/3) * (pi) * (L/2) * (W/2)^ 2, where Length >Width. Total tumor
burden volume per mouse was calculated as the sum of all tumor volumes
per mouse at each particular time point.
Study Approval. All mice were maintained and experiments were conducted
as approved by the Institutional Animal Care and Use Committee (IACUC) at
Memorial Sloan Kettering Cancer Center (MSKCC) under protocol nos. 11–06-
015 and 12–10-019.
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